PURPOSE: FIAU and FEAU were evaluated in vitro and in vivo as markers for HSV1-tk gene expression. METHODS: In vitro and biodistribution studies were performed in wild type and transduced HT-29 cells using [14C]FIAU and [3H]FEAU. PET imaging was performed using [18F]FIAU and [18F]FEAU. RESULTS: In vitro uptake of [14C]FIAU in tk-positive cells was 39-fold, 49-fold, and 43-fold higher (p<0.001) than in wild type cells at 30, 60, and 120 min, respectively. Uptake of [3H]FEAU in transduced cells was 46-fold, 62-fold, and 121-fold higher (p<0.001) than in wild type cells at the same time points. In vivo uptake of [14C]FIAU at 2 h in HSV1-tk positive tumors was 15.48+/-3.94, 6.7-fold higher (p<0.001) than in wild type tumors. Uptake of [3H]FEAU in transduced tumors was 9.98+/-1.99, 5.0-fold higher (p<0.001) than in wild type tumors. Micro-PET images using [18F]FIAU and [18F]FEAU also showed very high uptake in HSV-tk tumors. CONCLUSION: [18F]FIAU and [18F]FEAU appear to be potential PET imaging agents for gene expression.
PURPOSE: FIAU and FEAU were evaluated in vitro and in vivo as markers for HSV1-tk gene expression. METHODS: In vitro and biodistribution studies were performed in wild type and transduced HT-29 cells using [14C]FIAU and [3H]FEAU. PET imaging was performed using [18F]FIAU and [18F]FEAU. RESULTS: In vitro uptake of [14C]FIAU in tk-positive cells was 39-fold, 49-fold, and 43-fold higher (p<0.001) than in wild type cells at 30, 60, and 120 min, respectively. Uptake of [3H]FEAU in transduced cells was 46-fold, 62-fold, and 121-fold higher (p<0.001) than in wild type cells at the same time points. In vivo uptake of [14C]FIAU at 2 h in HSV1-tk positive tumors was 15.48+/-3.94, 6.7-fold higher (p<0.001) than in wild type tumors. Uptake of [3H]FEAU in transduced tumors was 9.98+/-1.99, 5.0-fold higher (p<0.001) than in wild type tumors. Micro-PET images using [18F]FIAU and [18F]FEAU also showed very high uptake in HSV-tk tumors. CONCLUSION: [18F]FIAU and [18F]FEAU appear to be potential PET imaging agents for gene expression.
Authors: M Namavari; J R Barrio; T Toyokuni; S S Gambhir; S R Cherry; H R Herschman; M E Phelps; N Satyamurthy1 Journal: Nucl Med Biol Date: 2000-02 Impact factor: 2.408
Authors: S S Gambhir; J R Barrio; M E Phelps; M Iyer; M Namavari; N Satyamurthy; L Wu; L A Green; E Bauer; D C MacLaren; K Nguyen; A J Berk; S R Cherry; H R Herschman Journal: Proc Natl Acad Sci U S A Date: 1999-03-02 Impact factor: 11.205
Authors: Juri Gelovani Tjuvajev; Mikhail Doubrovin; Timothy Akhurst; Shangde Cai; Julius Balatoni; Mian M Alauddin; Ronald Finn; William Bornmann; Howard Thaler; Peter S Conti; Ronald G Blasberg Journal: J Nucl Med Date: 2002-08 Impact factor: 10.057
Authors: J G Tjuvajev; N Avril; T Oku; T Sasajima; T Miyagawa; R Joshi; M Safer; B Beattie; G DiResta; F Daghighian; F Augensen; J Koutcher; J Zweit; J Humm; S M Larson; R Finn; R Blasberg Journal: Cancer Res Date: 1998-10-01 Impact factor: 12.701
Authors: Dean O Campbell; Shahriar S Yaghoubi; Ying Su; Jason T Lee; Martin S Auerbach; Harvey Herschman; Nagichettiar Satyamurthy; Johannes Czernin; Arnon Lavie; Caius G Radu Journal: J Biol Chem Date: 2011-11-09 Impact factor: 5.157
Authors: Ron Chen; Jesse J Parry; Walter J Akers; Mikhail Y Berezin; Issam M El Naqa; Samuel Achilefu; W Barry Edwards; Buck E Rogers Journal: J Nucl Med Date: 2010-08-18 Impact factor: 10.057
Authors: Peter Brader; Kaitlyn Kelly; Sheng Gang; Jatin P Shah; Richard J Wong; Hedvig Hricak; Ronald G Blasberg; Yuman Fong; Ziv Gil Journal: PLoS One Date: 2009-03-10 Impact factor: 3.240